A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants
Clinical trial NCT02927873 · COMPLETED
Trial details
- NCT number
- NCT02927873
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-11
- Primary completion
- 2019-02-19
- Enrollment
- 107
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.